Placental Transfer
Cross-source consensus on Placental Transfer from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Risks & contraindications
Evidence quality
Other
Highlighted claims
- The trial will assess human transfer by measuring DM199 in umbilical cord blood at birth and breastmilk within 24 hours postpartum. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
- Macromolecules such as proteins require specific carrier transport proteins to cross the syncytiotrophoblast surface of the placenta. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
- Rat reproductive toxicology found DM199 in maternal blood but not fetal blood after gestational administration. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
- DM199 is structurally unlikely to cross the placental barrier because it is a large protein molecule. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial